We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 37

Whistleblowers rewarded again by SEC and the judiciary

  • Epstein Becker Green
  • -
  • USA
  • -
  • September 11 2014

On August 29, 2014, two whistleblower developments of particular interest to health care and life science entities emerged from the Securities and

Expect Focus Vol. 1, Winter 2015: trademarks in Cuba, successful whistleblowers, big data, health care encryption, jury instruction tips

  • Carlton Fields Jorden Burt
  • -
  • USA
  • -
  • March 25 2015

New Jersey’s new data privacy standard, signed into law as S. 562 by Gov. Chris Christie on January 9, requires health insurance carriers that are

Supreme Court holds that issuers can be liable for omitting material facts from statements of opinion in Omnicare case

  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • -
  • USA
  • -
  • March 25 2015

In its opinion in Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, released yesterday, the U.S. Supreme Court held

2013 year-end Foreign Corrupt Practices Act update

  • Baker & Hostetler LLP
  • -
  • Libya, USA
  • -
  • February 10 2014

The third and fourth quarters of 2013 proved to be eventful and poten- tially prophetic as to the course the Foreign Corrupt Practices Act ("FCPA"

Third Circuit vacates dismissal of Celebrex securities fraud class action

  • Locke Lord LLP
  • -
  • USA
  • -
  • February 17 2009

The United States Court of Appeals for the Third Circuit (“Third Circuit”) recently vacated the dismissal of a securities fraud class action alleging that a pharmaceutical company, Pharmacia, Inc., made materially false statements about a clinical study of a popular anti-inflammatory medication

Denial of leave to amend securities complaint affirmed on basis of futility

  • Katten Muchin Rosenman LLP
  • -
  • USA
  • -
  • March 28 2008

The Court of Appeals for the Eighth Circuit affirmed a decision dismissing Plaintiff’s class action securities fraud complaint and denying Plaintiff leave to amend

Pleading still matters: Shareholders failed to properly plead scienter

  • Bricker & Eckler LLP
  • -
  • USA
  • -
  • April 1 2014

Despite the complexities involved in securities fraud actions, the Sixth Circuit recently reminded litigants that adequately pleading facts to

Insider trading developments - Summer 2014

  • Schulte Roth & Zabel LLP
  • -
  • USA
  • -
  • July 31 2014

The U.S. Securities and Exchange Commission and Department of Justice are continuing to investigate and prosecute insider trading cases at a rate not

Scienter inadequately pled under the standard set forth in the PSLRA

  • Katten Muchin Rosenman LLP
  • -
  • USA
  • -
  • October 8 2010

The U.S. District Court for the Southern District of Indiana dismissed plaintiff’s securities fraud action against a nationwide health care benefits provider, and its officers and directors, in which plaintiff alleged that defendants artificially inflated the price of the stock by making certain false and misleading statements

Matrixx Securities fraud case could affect product liability law

  • Squire Patton Boggs
  • -
  • USA
  • -
  • December 10 2010

Sometimes the most significant changes in the law come from unexpected places